Phase 3 N=61 A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash
Acne Vulgaris
Primary: Local Tolerability - Skin Dryness — 28; 26; 2; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,869 Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies
Chronic Hepatitis B
Primary: Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015] — 67.2; 73.8; 81.7; 86.3 Percentage of participants
Phase 3 N=430 A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)
Acute Pain Following a Total Abdominal Hysterectomy
Primary: Average Pain Intensity at Rest Over Days 1 to 3 — 2.40; 2.46; 3.26 Score on a scale — p=<0.001
Phase 3 N=199 n-3 Polyunsaturated Fatty Acids (PUFAs) in the Prevention of Atrial Fibrillation
Atrial Fibrillation
Primary: Probability of Maintenance of Sinus Rhythm at One-year Follow up.(Number of Patients Who Maintained Sinus Rhythm) — 61; 34 partecipants — p=< 0.05
Phase 3 N=1,088 A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
Hepatitis C
Primary: Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After…
Phase 3 N=36 Oral Progesterone for Prevention of Preterm Birth
Preterm Birth
Primary: Rate of Recurrent Preterm Birth — 5; 8 participants
Phase 3 N=540 A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
Hepatitis C
Primary: Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment…
Phase 3 N=511 Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts
Genital Warts
Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants
Phase 3 N=486 ViVEXX Carotid Revascularization Trial (VIVA)
Carotid Artery Stenosis
Primary: Percentage of Patients Experiencing Major Adverse Events (MAE) — 6.9 percentage of participants
Phase 3 N=437 A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Progression-Free Survival — 9.0; 11.3 Months
Phase 3 N=100 Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
Respiratory Syncytial Virus Infection · Premature Birth · Bronchopulmonary Dysplasia
Primary: Frequency of Adverse Events — 41 participants
Phase 3 N=118 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
Pneumococcal Vaccines
Primary: Geometric Mean Concentration (GMC) of Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibodies 1 Month After the Toddler Dose — 5.27; 5.06; 9.63; 8.75 mcg/mL
Phase 3 N=939 A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Objective Progression-free Survival (PFS) — 4.11; 2.83 months — p=0.00006
Phase 3 N=260 Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Survival Without Grade 3 or 4 Toxicity — 3.2; 0.7 months — p=<0.001
Phase 3 N=97 Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures
Partial Epilepsies · Partial Onset Seizures
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study (Maximum Study Duration 2 Years) — 93 subjects